Delivery Order SPE2DR25D1201-SPE2DR26FAJTX
Award Date 11/13/25
Potential Completion Date 11/14/25
Potential Value $31K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,444.93 for REPATHA 140 mg/ml SureClick auto-injector pens on September 11, 2025, with ultimate completion by September 12, 2025. This firm fixed price, non-set-aside delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk, typically administered via pre-filled...
- The Defense Logistics Agency awarded a $20,623.85 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $1,769.15 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract issued on August 5, 2025, with performance at the vendor's Conshohocken, Pennsylvania headquarters. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with established heart...
- The Defense Logistics Agency awarded a delivery order valued at $13,727.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. This non-competitive, firm fixed-price delivery order was awarded on September 9, 2025, with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk in eligible...
- The Defense Logistics Agency awarded a delivery order valued at $46,199.30 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with completion scheduled for August 29, 2025. This is a firm fixed-price, non-set-aside contract executed on August 28, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. REPATHA is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in eligible patient...
- The Defense Logistics Agency awarded a $61,885.07 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens on October 15, 2025, with a completion date of October 16, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. REPATHA is a prescription medication used to lower cholesterol levels in patients with cardiovascular disease, and the delivery will be fulfilled at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a $24,925.53 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed-price, competitively awarded contract was placed with no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick...
- The Defense Logistics Agency awarded a $53,478.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside competitive award is being performed at the company's corporate office in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a monoclonal antibody used to treat high cholesterol in patients with cardiovascular disease, and the SureClick...
- The Defense Logistics Agency awarded a $22,002.23 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of October 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. REPATHA (evolocumab) is a PCSK9 inhibitor used in cardiovascular disease...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with a ceiling value of $1,041.42. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to treat high cholesterol and reduce...